Meeting
2018 ASCO Annual Meeting
Comprehensive molecular and immunohistochemical analysis of advanced renal cell carcinoma patients treated with mTOR inhibitors.
Authors
Jesús GarcÃa-Donas
Fundacion Hospital de Madrid, Madrid, Spain
Jesús GarcÃa-Donas , Jose Maria Roldan , Nuria Lainez , Daniel E. Castellano , Emilio Esteban González , Miguel A. Climent , Javier Puente , Juan Francisco Rodriguez-Moreno , Teresa Alonso Gordoa , Aranzazu Gonzalez del Alba , Jose Angel Arranz , Maria Santos , Susana Hernando Polo , Montserrat Domenech , Laura Rodriguez , Alejandro Herrador , M Isabel Sáez , Enrique Gallardo Díaz , Ana Maria Gutierrez , Cristina Rodríguez-Antona
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4559)
DOI
10.1200/JCO.2018.36.15_suppl.4559
Abstract #
4559
Poster Bd #
385
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program.
First Author: Mark Andrew Dickson
Poster
2015 ASCO Annual Meeting
Activating genomic mutations in the mTOR pathway predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.
First Author: Andre Poisl Fay
Poster
2019 Genitourinary Cancers Symposium
Molecular stratification of high-grade unclassified renal cell carcinoma to improve prognostication and management strategy.
First Author: Yingbei Chen
Poster
2017 ASCO Annual Meeting
Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors.
First Author: Ecaterina Elena Ileana Dumbrava